Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Inogen Inc

Healthcare US INGN

5.98USD
-0.11(1.81%)

Last update at 2026-06-03T20:00:00Z

Day Range

5.886.25
LowHigh

52 Week Range

4.1311.98
LowHigh

Fundamentals

  • Previous Close 6.09
  • Market Cap202.76M
  • Volume438266
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.41400M
  • Revenue TTM321.52M
  • Revenue Per Share TTM13.81
  • Gross Profit TTM 153.53M
  • Diluted EPS TTM-4.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -83.26800M 8.66M -5.28000M 24.27M 40.45M
Minority interest - - - - -
Net income -83.77200M -6.33300M -5.82900M 20.95M 51.84M
Selling general administrative 43.91M 37.85M 38.60M 37.12M 38.02M
Selling and marketing expenses 120.77M 112.81M 97.52M 105.55M 95.64M
Gross profit 153.53M 176.48M 138.18M 171.86M 178.58M
Reconciled depreciation 23.51M 21.63M 18.58M 13.83M 11.29M
Ebit 19.08M -12.38800M -30.60600M 5.96M 26.60M
Ebitda 42.59M 9.24M -12.02500M 19.79M 37.89M
Depreciation and amortization 23.51M 21.63M 18.58M 13.83M 11.29M
Non operating income net other 1.98M -0.58100M 6.75M 4.48M 2.56M
Operating income 19.08M -12.38800M -12.02500M 5.96M 37.89M
Other operating expenses 410.32M 348.76M 320.51M 342.15M 320.22M
Interest expense 2.84M 21.05M 25.33M 18.32M 0.00000M
Tax provision 0.50M 14.99M 0.55M 3.32M -11.39000M
Interest income 2.84M 0.13M 0.91M 4.71M 3.26M
Net interest income 2.84M 0.13M 0.91M 4.71M 3.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.50M 14.99M 0.55M 3.32M -11.39000M
Total revenue 377.24M 358.00M 308.49M 361.94M 358.11M
Total operating expenses 186.62M 167.24M 150.21M 152.07M 140.69M
Cost of revenue 223.71M 181.52M 170.31M 190.08M 179.53M
Total other income expense net -102.34700M 21.05M 6.75M 18.32M -0.69600M
Discontinued operations - - - - -
Net income from continuing ops -83.77200M -6.33300M -5.82900M 20.95M 51.84M
Net income applicable to common shares -83.77200M -6.33300M -5.82900M 20.95M 51.84M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 326.19M 405.04M 489.51M 461.85M 447.34M
Intangible assets 34.59M 0.18M 60.15M 68.80M 77.53M
Earning assets - - - - -
Other current assets 14.52M 19.19M 26.00M 17.90M 10.16M
Total liab 121.38M 107.64M 119.29M 112.23M 102.72M
Total stockholder equity 204.81M 297.41M 370.23M 349.62M 344.62M
Deferred long term liab - - - 0.03M 0.09M
Other current liab 60.86M 18.98M 23.86M 14.07M 11.96M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -116.94900M -14.50000M 69.27M 75.61M 81.43M
Other liab - 22.52M 34.49M 47.44M 47.84M
Good will 10.06M 32.85M 32.98M 33.16M 32.95M
Other assets - 2.44M 3.36M 17.14M 19.34M
Cash 125.49M 187.01M 235.52M 211.96M 198.04M
Cash and equivalents - - - - -
Total current liabilities 72.50M 65.35M 61.51M 56.71M 50.18M
Current deferred revenue 7.98M 8.88M 8.57M 6.99M 5.48M
Net debt -103.56900M -163.73500M -208.85000M -201.95300M -191.32100M
Short term debt 3.65M 3.52M 3.39M 1.93M 2.01M
Short long term debt - - - - -
Short long term debt total 21.92M 23.28M 26.67M 10.01M 6.72M
Other stockholder equity 320.51M 312.13M 299.46M 273.52M 263.25M
Property plant equipment - 43.27M 38.93M 28.23M 19.44M
Total current assets 207.07M 304.64M 329.19M 305.70M 292.22M
Long term investments - - - - -
Net tangible assets - 264.38M 277.10M 247.66M 234.13M
Short term investments 2.98M 0.00000M 9.99M 19.26M 11.06M
Net receivables 42.24M 64.35M 25.80M 31.77M 37.30M
Long term debt - - - - -
Inventory 21.84M 34.09M 31.87M 24.82M 35.66M
Accounts payable 0.03M 33.97M 25.69M 33.71M 30.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.23M -0.24300M 1.47M 0.47M -0.08700M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - -14.50000M 69.27M 75.61M 81.43M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.83M 2.44M 3.36M 2.67M 4.89M
Deferred long term asset charges - - - - 14.45M
Non current assets total 119.13M 100.40M 160.33M 156.16M 155.12M
Capital lease obligations 21.92M 23.28M 26.67M 10.01M 6.72M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -10.87700M 9.27M -8.20600M 32.66M -12.70700M
Change to liabilities 0.57M 2.61M -4.64100M -2.38900M 11.06M
Total cashflows from investing activities -10.87700M -14.64500M -25.64000M -44.05700M -24.96500M
Net borrowings - - - - -
Total cash from financing activities 0.38M 15.00M 2.07M 4.93M 18.30M
Change to operating activities 6.97M 2.14M 5.34M -6.87600M 1.85M
Net income -83.77200M -6.33300M -5.82900M 20.95M 51.84M
Change in cash -48.51000M 23.56M 13.93M 1.40M 53.68M
Begin period cash flow 235.52M 211.96M 198.04M 196.63M 142.95M
End period cash flow 187.01M 235.52M 211.96M 198.04M 196.63M
Total cash from operating activities -37.53200M 23.63M 37.01M 40.59M 59.98M
Issuance of capital stock - - - - -
Depreciation 23.51M 21.63M 18.58M 13.83M 11.29M
Other cashflows from investing activities -17.55400M -18.43200M -13.04900M -73.57800M -4.21500M
Dividends paid - - - - -
Change to inventory -5.60100M -10.77500M 7.59M -10.33600M -9.97200M
Change to account receivables -51.33700M -6.12700M -8.17700M -16.70700M -25.96300M
Sale purchase of stock 1.74M 15.65M 2.42M 5.86M 19.50M
Other cashflows from financing activities 0.38M 15.00M 2.07M 4.93M 18.30M
Change to netincome 51.33M 15.79M 12.94M 15.95M 3.81M
Capital expenditures 21.22M 24.07M 17.60M 6.51M 12.97M
Change receivables -51.33700M -6.12700M -8.17700M -16.70700M -25.96300M
Cash flows other operating 27.77M 6.84M 16.55M 19.29M 17.90M
Exchange rate changes - - - - -
Cash and cash equivalents changes -48.02900M 23.99M 13.44M 1.47M 53.31M
Change in working capital -44.72000M -20.06500M -0.03100M -27.88500M -25.64900M
Stock based compensation 12.28M 10.94M 8.20M 9.13M 12.79M
Other non cash items 55.16M 3.02M 16.17M 21.69M 21.29M
Free cash flow -58.75400M -0.43400M 19.42M 34.08M 47.00M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INGN
Inogen Inc		 -0.11 1.81% 5.98 - - 0.54 0.84 0.21 -1.1165
ABT
Abbott Laboratories		 3.11 3.58% 90.10 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 5.55 1.88% 300.55 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 3.60 4.62% 81.55 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.76 1.58% 48.45 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Inogen Inc

859 Ward Drive, Goleta, CA, United States, 93111

Key Executives

Name Title Year Born
Mr. Nabil Shabshab CEO, Pres & Director 1965
Ms. Alison Perry Bauerlein Co-Founder 1981
Mr. Bart Sanford Exec. VP of Operations 1966
Dr. Stanislav Glezer M.D., MBA Exec. VP & CTO 1973
Mr. George J. Parr Exec. VP & Chief Commercial Officer 1971
Ms. Kristin A. Caltrider Exec. VP, CFO & Treasurer 1968
Ms. Agnes Lee Sr. VP of Investor Relations & Strategic Planning NA
Mr. Jason Somer Exec. VP, Gen. Counsel & Corp. Sec. 1968
Ms. Jennifer Yi Boyer Exec. VP & Chief HR Officer NA
Mr. Matthew Pigeon Investor Relations Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions